Three deals worth a combined $19.5 billion were announced in a single day. Bristol Myers Squibb formed the largest China-to-West licensing partnership in biopharma history, paying $600 million upfront to co-develop 13 early-stage programs across oncology, hematology, and immunology with Jiangsu Hengrui Pharmaceuticals. Total potential deal value including milestones: up to $15.2 billion. Hengrui shares surged more than 13% in Hong Kong. Meanwhile, Isomorphic Labs—the AI drug discovery company spun out of Google DeepMind—raised $2.1 billion in Series B funding, the largest AI drug discovery round ever, bringing total funding to $2.7 billion. UCB announced a $2.2 billion acquisition of Candid Therapeutics for autoimmune T-cell engager assets, its second major deal in under a month. MacroGenics sold its manufacturing operations to a Taiwanese CDMO for $122.5 million, illustrating a growing trend of biotechs divesting production to preserve pipeline capital. And Roche partnered with PathAI to deploy AI-powered pathology for cancer diagnosis. Every vertical moved today.
Top Story: BMS and Hengrui Partner on 13 Programs in $15.2B Deal
What Happened: Bristol Myers Squibb announced a broad strategic partnership with Jiangsu Hengrui Pharmaceuticals on May 12, paying $600 million upfront to co-develop 13 early-stage programs spanning oncology, hematology, and immunology. Total potential deal value, including development and commercial milestones, is up to $15.2 billion. BMS gains exclusive development and commercialization rights outside Greater China. Hengrui retains rights in Greater China.
Why 13 Programs at Once Is Unprecedented
Most pharma licensing deals involve a single asset or a small handful of related programs. Thirteen programs in a single transaction is a portfolio-level bet that treats Hengrui as a strategic pipeline source rather than a one-off licensor. The breadth tells you something about BMS’s pipeline urgency: the company is not looking for a single compound to address a specific gap. It is looking for a broad set of early-stage options across its three priority therapeutic areas simultaneously.
BioPharm International noted that the deal includes programs in oncology, hematology, and immunology, though specific targets and development stages for individual programs were not fully disclosed at announcement. The $15.2 billion in total milestone potential implies BMS sees multiple blockbuster candidates within the 13-program portfolio—the milestone structure would not support that level of total value if BMS expected most programs to fail in development.
BMS’s Pipeline Pressure
BMS has been under sustained pressure to replenish its pipeline. The company’s two largest revenue generators—Revlimid and Eliquis—face ongoing generic erosion. The Opdivo franchise remains strong but faces increasing competition in immuno-oncology.
The Hengrui deal provides a broad set of early-stage options that could feed BMS’s pipeline for years. At the early stage, the cost per program is relatively low (the $600 million upfront divided across 13 programs implies roughly $46 million per program on average—a modest upfront investment for any single clinical-stage asset). The risk per program is high (most early-stage programs fail), but the portfolio approach provides diversification: BMS does not need all 13 to succeed. If even two or three produce registrational-quality candidates, the deal economics work.
The China Licensing Model Is Now Established
The BMS/Hengrui deal cements Chinese biotech licensing as a standard pipeline strategy for large Western pharma companies. The pattern has been building throughout 2026. Lilly licensed obesity assets from Hengrui through the Kailera vehicle that produced a $625 million IPO. AbbVie acquired Nav1.8 pain inhibitors from Haisco. GSK licensed the ALK7 siRNA SA030 from SiranBio for up to $1 billion. BMS’s $15.2 billion total deal value is the largest single transaction in this category by a wide margin.
The strategic logic is consistent across all of these deals: Chinese pharmaceutical companies are producing high-quality clinical-stage assets at lower development costs than Western biotech. Western companies get pipeline optionality and access to mechanisms they have not developed internally. Chinese companies get upfront cash and downstream milestone and royalty economics. The geopolitical risk is real—ongoing debates around the BIOSECURE Act, Section 232 tariff dynamics, and intellectual property transfer concerns—but that risk has not slowed deal flow. If anything, the pace of China-to-West licensing is accelerating.
Our Pro brief includes the full China licensing scorecard comparing BMS/Hengrui to Lilly/Hengrui, AbbVie/Haisco, and GSK/SiranBio across upfront payments, total deal value, and therapeutic areas. [Details below.]
What to Watch
Thirteen programs is a large portfolio to manage. Watch which programs BMS prioritizes for IND-enabling studies and how quickly the first candidates advance into clinical development. The attrition rate across 13 early-stage programs will determine whether the $600 million upfront was a strategic bargain or an expensive option on a portfolio with a low hit rate. Hengrui’s stock reaction (+13% in Hong Kong) signals that the Chinese market views the deal as highly favorable for the licensor, which is worth noting when evaluating the economics from BMS’s perspective.
Isomorphic Labs Raises $2.1B in Largest AI Drug Discovery Round Ever
What Happened: Isomorphic Labs, the London-based AI drug discovery company spun out of Google DeepMind, raised $2.1 billion in Series B funding. The round was led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This follows a $600 million Series A completed one year ago, bringing total funding to $2.7 billion.
What Isomorphic Is Building
Isomorphic uses technology derived from AlphaFold, DeepMind’s protein structure prediction platform that won the 2024 Nobel Prize in Chemistry. The company’s thesis is that the same AI architectures that predicted protein structures can be applied to drug design—predicting how small molecules interact with biological targets, designing novel compounds, and optimizing candidates for clinical properties.
The company has existing partnerships with Eli Lilly and Novartis but has been notably secretive about its internal pipeline. With $2.7 billion in total funding and no disclosed clinical-stage candidates, Isomorphic is the most heavily capitalized pre-clinical AI drug discovery company in the world. The bet is that AlphaFold-derived capabilities, applied to drug design rather than protein prediction, can produce clinical candidates that are fundamentally better than what traditional medicinal chemistry generates.
The 3.5x Step-Up in 12 Months
The progression from $600 million Series A to $2.1 billion Series B in 12 months represents a 3.5x step-up in round size. That acceleration signals explosive investor confidence in AI-native drug discovery as a category, not just in Isomorphic as a company. The participation of the UK Sovereign AI Fund adds a government-backed dimension to the investment thesis, reflecting national strategic interest in maintaining leadership in AI-driven healthcare.
The AI Drug Discovery Capital Wave in Context
Isomorphic’s round is the largest single financing in AI drug discovery history. But it is part of a broader capital wave that has defined 2026. Anthropic acquired Coefficient Bio for $400 million in April, embedding biology-native AI expertise at the model level. Novartis CEO Narasimhan joined Anthropic’s board, adding pharma governance to the AI company’s structure. Lilly’s collaboration with Profluent Bio ($2.25 billion in milestones) is applying AI to gene editing. The total capital flowing into AI drug discovery in 2026 is unprecedented by any measure.
Whether the thesis is correct—whether AI can meaningfully compress the drug development timeline by designing better molecules, predicting better targets, and reducing clinical attrition—remains an open question. The capital is flowing as if the answer is yes.
Our Pro brief analyzes where Isomorphic fits in the AI drug discovery capital stack alongside Anthropic, Recursion, and Lilly’s platform deals, and what $2.7 billion in funding implies about investor expectations for timeline to clinical-stage programs. [Details below.]
UCB Acquires Candid Therapeutics for $2.2B
What Happened: UCB announced a $2.2 billion acquisition of Candid Therapeutics, adding bispecific T-cell engager (TCE) assets targeting autoimmune diseases. The lead program, cizutamig, is a BCMA/CD3-targeting antibody in early-stage clinical trials for autoimmune conditions.
UCB’s Second Major Deal in Under a Month
This is UCB’s second major acquisition since mid-April. The company acquired Neurona Therapeutics for up to $1.15 billion on April 17, adding cell therapy for drug-resistant epilepsy. Combined M&A deployment in under a month: more than $3.3 billion.
For UCB, a mid-cap pharma company, $3.3 billion in acquisitions in under a month is a significant capital commitment that signals strategic urgency. The company is building a next-generation immunology and neuroscience pipeline while its existing franchises—Bimzelx (psoriasis) and Rystiggo (myasthenia gravis)—generate the cash flow to fund the buildout.
The Candid deal adds autoimmune TCE assets to UCB’s immunology portfolio. T-cell engagers have demonstrated “transformative efficacy” in autoimmune diseases—single treatment cycles producing durable remissions in conditions that previously required chronic therapy. The BCMA/CD3 mechanism targets the same pathway that has shown remarkable results in multiple myeloma (Tecvayli, Elrexfio) and is now being explored in autoimmune indications where B-cell depletion could reset the immune system.
Manufacturing Trend: MacroGenics Sells Factory to CDMO
What Happened: MacroGenics agreed to sell its GMP manufacturing operations to Taiwanese contract manufacturer Bora Pharmaceuticals for $122.5 million upfront. The Pharma Letter noted this is part of “a broader effort to slim down operations and preserve cash for its drug pipeline.”
Why Biotechs Are Divesting Manufacturing
The MacroGenics/Bora deal illustrates a growing trend: clinical-stage biotechs are divesting manufacturing assets to CDMOs rather than bearing the capital burden of maintaining in-house production. The economics are straightforward. Maintaining a GMP manufacturing facility requires ongoing investment in equipment, compliance, quality systems, and personnel regardless of whether the facility is running at full capacity. For a clinical-stage company with limited revenue, that fixed cost competes directly with pipeline R&D spending.
By selling to a CDMO, MacroGenics converts a capital-intensive fixed asset into upfront cash ($122.5 million) and presumably a manufacturing services agreement that converts production costs from fixed to variable. The company pays for manufacturing when it needs it rather than maintaining capacity whether or not it is utilized.
For Bora, the acquisition adds biologics manufacturing capacity in the United States at a time when domestic production capability is increasingly valued under the Section 232 tariff framework. CDMOs with U.S.-based facilities can offer tariff-advantaged manufacturing to sponsors that might otherwise face 15% to 100% duties on imported products.
Diagnostics: Roche Partners with PathAI for AI-Powered Cancer Diagnosis
Roche announced a partnership with PathAI to offer AI-powered pathology tools as part of its cancer diagnosis and tailored treatment offerings. PathAI’s platform uses machine learning to analyze tissue samples, identify biomarkers, and guide treatment selection.
Why This Matters: This is one of the most concrete diagnostics-AI integrations announced in 2026. AI-powered companion diagnostics could improve the speed and accuracy of biomarker-driven treatment matching, particularly for ADCs and targeted therapies where patient selection is critical to efficacy. The integration of AI into the pathology workflow bridges the gap between digital pathology platforms and clinical decision-making at the point of treatment selection.
Strategic Themes
1. China-to-West Licensing Is Now a Standard Pipeline Strategy for Large Pharma
BMS joining Lilly, AbbVie, and GSK in executing major China licensing deals cements the model as an established pipeline strategy rather than an experimental approach. Chinese pharmaceutical companies are producing clinical-stage assets across oncology, immunology, metabolic disease, pain, and cardiometabolic categories at a pace and quality level that Western pharma companies find strategically valuable. Geopolitical risks have not slowed deal flow. The BMS/Hengrui deal—13 programs, $15.2 billion in total potential value—is the largest expression of this thesis to date.
2. AI Drug Discovery Capital Is Accelerating Faster Than Any Therapeutic Category
Isomorphic’s $2.1 billion round, Anthropic’s Coefficient Bio acquisition, Lilly’s Profluent and Insilico deals, and the broader capital deployment into computational drug discovery collectively represent the largest investment thesis in biopharma outside of GLP-1 obesity. The question is no longer whether AI can contribute to drug development—it is how quickly AI-native platforms can produce clinical candidates that outperform traditional approaches. The companies that answer that question with data will define the next generation of pharmaceutical R&D.
3. UCB Is Deploying Capital Faster Than Companies Twice Its Size
$3.3 billion in M&A in under a month from a mid-cap pharma company is an aggressive pace by any standard. UCB is building across two frontier therapeutic areas simultaneously—autoimmune TCE (Candid) and epilepsy cell therapy (Neurona)—while maintaining its core Bimzelx and Rystiggo franchises. The strategy is high-conviction and high-risk: if both acquisitions produce approved products, UCB transforms into a significantly larger company. If either falters, the capital deployment becomes a drag on a mid-cap balance sheet with limited margin for error.
4. Biotechs Divesting Manufacturing Reflects a Structural Shift in the Industry’s Capital Model
MacroGenics selling its factory to Bora is part of a broader recognition that clinical-stage biotechs should not be in the manufacturing business. The capital required to maintain GMP facilities competes with pipeline R&D. CDMOs are better positioned to operate manufacturing at scale and spread fixed costs across multiple clients. The Section 232 tariff framework adds another incentive: CDMOs with U.S.-based facilities can offer tariff-advantaged production that sponsors with overseas manufacturing cannot. The trend will accelerate as more biotechs conclude that their competitive advantage lies in drug development, not drug production.
Frequently Asked Questions
What is the BMS/Hengrui deal?
BMS paid $600 million upfront to co-develop 13 early-stage programs spanning oncology, hematology, and immunology with China’s Hengrui Pharmaceuticals. Total potential deal value is up to $15.2 billion. BMS gains exclusive rights outside Greater China. It is one of the largest China-to-West licensing transactions in biopharma history. Hengrui shares surged more than 13% in Hong Kong.
Why is BMS licensing 13 programs at once?
BMS faces pipeline pressure as Revlimid and Eliquis undergo generic erosion. Thirteen programs provides a broad portfolio of early-stage options across three therapeutic areas at a relatively modest cost per program (roughly $46 million per program on average at the upfront level). The portfolio approach provides diversification—BMS does not need all 13 to succeed for the deal to generate value.
What is Isomorphic Labs?
The AI drug discovery company spun out of Google DeepMind that uses AlphaFold-derived technology for drug design. It raised $2.1 billion in Series B funding (largest AI drug discovery round ever), bringing total funding to $2.7 billion. The round was led by Thrive Capital with Alphabet, Temasek, and the UK Sovereign AI Fund. Isomorphic has partnerships with Lilly and Novartis but has not disclosed its internal pipeline.
What did UCB acquire?
Candid Therapeutics for $2.2 billion. Candid’s lead program cizutamig is a BCMA/CD3-targeting bispecific T-cell engager for autoimmune diseases. This is UCB’s second major deal in under a month (after Neurona Therapeutics for $1.15 billion), bringing total M&A deployment above $3.3 billion.
Why did MacroGenics sell its manufacturing?
To preserve cash for pipeline development. Maintaining GMP manufacturing requires significant ongoing investment regardless of capacity utilization. Selling to Bora Pharmaceuticals for $122.5 million converts a fixed-cost asset into upfront cash and (presumably) a variable-cost manufacturing agreement. Bora gains U.S.-based biologics capacity valued under the Section 232 tariff framework.
What is the Roche/PathAI partnership?
Roche will offer PathAI’s AI-powered pathology tools for cancer diagnosis and tailored treatment. PathAI uses machine learning to analyze tissue samples, identify biomarkers, and guide treatment selection. This is one of the most concrete diagnostics-AI integrations of 2026.
Is Chinese biotech licensing politically risky?
Geopolitical concerns are real—BIOSECURE Act debates, Section 232 tariff dynamics, and IP transfer questions are ongoing. But the risk has not slowed deal flow. BMS, Lilly, AbbVie, and GSK have all executed major China licensing deals in 2026. The pace is accelerating, suggesting that large pharma companies have concluded the pipeline value outweighs the geopolitical risk.
When is ASCO?
May 29 through June 2 in Chicago. Revolution Medicines presents full Phase 3 RASolute 302 data in a plenary session on May 31. The conference is 18 days away.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
China Licensing Scorecard. We compile every major China-to-West licensing deal of 2026—BMS/Hengrui, Lilly/Hengrui, AbbVie/Haisco, GSK/SiranBio, and others—into a single framework comparing upfront payments, total milestone values, therapeutic areas, and geopolitical risk positioning. If you are evaluating China-sourced assets, this is the competitive landscape.
AI Drug Discovery Capital Stack. We map Isomorphic’s $2.7B alongside Anthropic’s Coefficient Bio, Recursion’s trajectory, Lilly’s Profluent deal, and the broader computational biology financing wave into an analysis of where the capital is going, what it expects in return, and how quickly AI-native platforms need to produce clinical candidates to justify these valuations.
UCB’s $3.3B Sprint. We analyze why the Belgian mid-cap is deploying capital faster than companies twice its size, how the Candid TCE and Neurona cell therapy acquisitions fit the immunology/neuroscience thesis, and what the M&A pace means for UCB’s balance sheet and growth trajectory.
Plus: MacroGenics/Bora manufacturing trend analysis, Roche/PathAI diagnostics integration, ASCO 18-day countdown, Makary status update, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
